BGOG-cx-11

A randomized, Phase 3, double-blind study of radiochemotherapy with or without Pembrolizumab for the treatment of high-risk, locally advanced cervical cancer

Sponsor: Merck Sharp & Dohme Corp.

Participating sites:

  • AZ Sint-Lucas, Gent
  • UZ Leuven, Leuven
  • GZA campus Sint-Augustinus, Antwerpen
  • OLV Aalst, Aalst
  • CHU Ambroise Paré, Mons
  • UZA, Antwerpen